The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sodium valproate     sodium 2-propylpentanoate

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of VALPROIC ACID


Psychiatry related information on VALPROIC ACID


High impact information on VALPROIC ACID


Chemical compound and disease context of VALPROIC ACID


Biological context of VALPROIC ACID


Anatomical context of VALPROIC ACID


Associations of VALPROIC ACID with other chemical compounds


Gene context of VALPROIC ACID


Analytical, diagnostic and therapeutic context of VALPROIC ACID


  1. Acute hepatic failure associated with the use of sodium valproate. Suchy, F.J., Balistreri, W.F., Buchino, J.J., Sondheimer, J.M., Bates, S.R., Kearns, G.L., Stull, J.D., Bove, K.E. N. Engl. J. Med. (1979) [Pubmed]
  2. Anticonvulsants specific for petit mal antagonize epileptogenic effect of leucine enkephalin. Snead, O.C., Bearden, L.J. Science (1980) [Pubmed]
  3. Pure red cell aplasia associated with sodium valproate therapy. MacDougall, L.G. JAMA (1982) [Pubmed]
  4. Sodium valproate, pregnancy, and infantile fatal liver failure. Legius, E., Jaeken, J., Eggermont, E. Lancet (1987) [Pubmed]
  5. Acute liver disease associated with sodium valproate. Ware, S., Millward-Sadler, G.H. Lancet (1980) [Pubmed]
  6. Nocturnal enuresis associated with sodium valproate. Panayiotopoulos, C.P. Lancet (1985) [Pubmed]
  7. Sodium valproate in Huntington's disease. Symington, G.R., Leonard, D.P., Shannon, P.J., Vajda, F.J. The American journal of psychiatry. (1978) [Pubmed]
  8. Effect of sodium valproate in three patients with organic brain syndromes. Kahn, D., Stevenson, E., Douglas, C.J. The American journal of psychiatry. (1988) [Pubmed]
  9. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. Herridge, P.L., Pope, H.G. Journal of clinical psychopharmacology. (1985) [Pubmed]
  10. Sodium valproate as an antidepressant. Kemp, L.I. The British journal of psychiatry : the journal of mental science. (1992) [Pubmed]
  11. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. Callaghan, N., Garrett, A., Goggin, T. N. Engl. J. Med. (1988) [Pubmed]
  12. Cutaneous vasculitis induced by sodium valproate. Kamper, A.M., Valentijn, R.M., Strickler, B.H., Purcell, P.M. Lancet (1991) [Pubmed]
  13. Hepatitis A in three patients taking sodium valproate. Dowling, S.J. Lancet (1984) [Pubmed]
  14. Sodium valproate and heterogeneity of pituitary dependent Cushing's syndrome. Koppeschaar, H.P., Croughs, R.J., Thijssen, J.H., Schwarz, F. Lancet (1982) [Pubmed]
  15. Sodium valproate and platelet-count. Raworth, R.E., Birchall, G. Lancet (1978) [Pubmed]
  16. Benign versive or circling epilepsy with bilateral 3-cps spike-and-wave discharges in late childhood. Gastaut, H., Aguglia, U., Tinuper, P. Ann. Neurol. (1986) [Pubmed]
  17. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Nagao, T., Ohshimo, T., Mitsunobu, K., Sato, M., Otsuki, S. Biol. Psychiatry (1979) [Pubmed]
  18. The effects of sodium valproate on plasma somatostatin and insulin in humans. Kusunoki, M., Yamamura, T., Ichii, S., Fujita, S., Nakai, T., Utsunomiya, J. J. Clin. Endocrinol. Metab. (1988) [Pubmed]
  19. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Roh, M.S., Eom, T.Y., Zmijewska, A.A., De Sarno, P., Roth, K.A., Jope, R.S. Biol. Psychiatry (2005) [Pubmed]
  20. Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures. Redenbaugh, J.E., Sato, S., Penry, J.K., Dreifuss, F.E., Kupferberg, H.J. Neurology (1980) [Pubmed]
  21. Pharmacokinetics and bioavailability of sodium valproate. Klotz, U., Antonin, K.H. Clin. Pharmacol. Ther. (1977) [Pubmed]
  22. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Monks, A., Richens, A. Clin. Pharmacol. Ther. (1980) [Pubmed]
  23. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Perucca, E., Hebdige, S., Frigo, G.M., Gatti, G., Lecchini, S., Crema, A. Clin. Pharmacol. Ther. (1980) [Pubmed]
  24. Inhibitory effects of sodium valproate on oxidative phosphorylation. Haas, R., Stumpf, D.A., Parks, J.K., Eguren, L. Neurology (1981) [Pubmed]
  25. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Armeanu, S., Bitzer, M., Lauer, U.M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., Steinle, A., Salih, H.R. Cancer Res. (2005) [Pubmed]
  26. Sodium valproate and bone marrow suppression. Smith, F.R., Boots, M. Ann. Neurol. (1980) [Pubmed]
  27. Naloxone reverses the inhibition by sodium valproate of GABA transport across the Deiters' neuronal plasma membrane. Hydén, H., Cupello, A., Palm, A. Ann. Neurol. (1987) [Pubmed]
  28. Human brain, plasma, and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy. Vajda, F.J., Donnan, G.A., Phillips, J., Bladin, P.F. Neurology (1981) [Pubmed]
  29. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Scott, J., Pope, M. The American journal of psychiatry. (2002) [Pubmed]
  30. Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids. Perlman, B.J., Goldstein, D.B. Mol. Pharmacol. (1984) [Pubmed]
  31. Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation. Armijo, J.A., Herranz, J.L., Arteaga, R., Valiente, R. Clinical pharmacokinetics. (1986) [Pubmed]
  32. Sodium valproate and clonazepam in the treatment of intractable epilepsy. Lance, J.W., Anthony, M. Arch. Neurol. (1977) [Pubmed]
  33. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. Hassel, B., Iversen, E.G., Gjerstad, L., Taubøll, E. J. Neurochem. (2001) [Pubmed]
  34. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. MacFarlane, M., Inoue, S., Kohlhaas, S.L., Majid, A., Harper, N., Kennedy, D.B., Dyer, M.J., Cohen, G.M. Cell Death Differ. (2005) [Pubmed]
  35. Cholinergic stimulation of early growth response-1 DNA binding activity requires protein kinase C and mitogen-activated protein kinase kinase activation and is inhibited by sodium valproate in SH-SY5Y cells. Grimes, C.A., Jope, R.S. J. Neurochem. (1999) [Pubmed]
  36. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. Bosetti, F., Weerasinghe, G.R., Rosenberger, T.A., Rapoport, S.I. J. Neurochem. (2003) [Pubmed]
  37. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. Grimes, C.A., Jope, R.S. J. Neurochem. (2001) [Pubmed]
  38. Opioid modulation of the gamma-aminobutyric acid-controlled inhibition of exercise-stimulated growth hormone and prolactin secretion in normal men. Coiro, V., Volpi, R., Maffei, M.L., Caiazza, A., Caffarri, G., Capretti, L., Colla, R., Chiodera, P. Eur. J. Endocrinol. (1994) [Pubmed]
  39. Lowered erythrocyte-sedimentation rate with sodium valproate. Hutchinson, R.M., Clay, C.M., Simpson, M.R., Wood, J.K. Lancet (1978) [Pubmed]
  40. Sodium valproate: serial monitoring of EEG and serum levels. Rowan, A.J., Binnie, C.D., de Beer-Pawlikowski, N.K., Goedhart, D.M., Gutter, T., van der Geest, P., Meinardi, H., Meijer, J.W. Neurology (1979) [Pubmed]
  41. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Jensen, R., Brinck, T., Olesen, J. Neurology (1994) [Pubmed]
  42. Rectal administration of sodium valproate in status epilepticus. Beran, R.G. Neurology (1980) [Pubmed]
WikiGenes - Universities